Contact Us

Yes. sAC rescue experiments require attention to the soluble cyclase architecture: • Construct design: use a codon-modified ADCY10 sequence with a small C-terminal tag (FLAG, HA). sAC has tandem cyclase domains (C1, C2) forming the active site, plus regulatory regions — preserve all elements; note that full-length sAC exists alongside multiple shorter isoforms (sACt, soluble truncated forms) that retain catalytic activity. • Catalytically-dead rescue: active site metal-binding aspartate mutations abolish cyclase activity. • Bicarbonate-insensitive rescue: HCO₃⁻-binding site mutations separate bicarbonate sensing from catalytic activity. • Functional readout: rescue should restore HCO₃⁻-induced cAMP elevation. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying ABCC1 (MRP1, multidrug resistance protein 1)'s role as a multidrug efflux transporter or modeling its functions in drug resistance and physiological transport. The Knockout line is the standard tool for asking whether ABCC1/MRP1 is required for these processes — ABCC1/MRP1 is an ATP-binding cassette transporter that effluxes glutathione conjugates, glucuronides, sulfates, and a broad range of chemotherapeutics (doxorubicin, vincristine, etoposide, methotrexate); MRP1 is one of the three major drug-efflux ABC transporters (with ABCB1/P-gp and ABCG2/BCRP) and a key mediator of multidrug resistance in cancer. Overexpression is useful for studying ABCC1 gain-of-function effects. For multidrug resistance research, the EDITGENE ABCC1 Knockout in HEK293 is uniquely valuable — this product completes EDITGENE's three-major-ABC-efflux-transporter toolkit alongside ABCB1/P-gp and ABCG2/BCRP (all in HEK293). Rescue with wild-type or transport-deficient ABCC1 enables structure-function studies. The knockout is a critical specificity tool for studying MRP1-mediated chemotherapy resistance, MRP1 inhibitors (MK-571, reversan), glutathione-conjugate transport, and emerging MRP1-targeted approaches in drug resistance.

Yes. ABCC1/MRP1 rescue experiments are well-established for drug transporter research: • Construct design: use a codon-modified ABCC1 sequence with a small intracellular tag (FLAG, HA). MRP1 is a full ABC transporter with three membrane-spanning domains and two nucleotide-binding domains — preserve membrane topology. • Surface localization validation: confirm plasma membrane localization before efflux assays. • Transport-deficient rescue: Walker A/B motif mutations abolish ATP-dependent transport. • Functional readout: rescue should restore substrate efflux measured by calcein-AM or doxorubicin accumulation assays. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying ABCG2 (BCRP, breast cancer resistance protein)'s role as a multidrug efflux transporter or modeling its functions in drug resistance, pharmacokinetics, and uric acid transport. The Knockout line is the standard tool for asking whether ABCG2/BCRP is required for these processes — ABCG2 is an ATP-binding cassette (ABC) half-transporter that functions as a homodimer to efflux a broad range of substrates including chemotherapeutics (mitoxantrone, topotecan, methotrexate, tyrosine kinase inhibitors), dietary xenobiotics, and urate; ABCG2 is highly expressed at the blood-brain barrier, placenta, intestine, and liver, critically influencing drug absorption, distribution, and resistance. Overexpression is useful for studying ABCG2 gain-of-function effects. For drug resistance and pharmacokinetics research, the EDITGENE ABCG2 Knockout in HEK293 is uniquely valuable — ABCG2/BCRP is one of the three major drug-efflux ABC transporters (with ABCB1/P-gp and ABCC1/MRP1). Rescue with wild-type, transport-deficient, or the common Q141K polymorphism (reduced function, associated with gout and altered drug pharmacokinetics) ABCG2 enables comprehensive structure-function and pharmacogenomic studies. The knockout is a critical specificity tool for studying multidrug resistance, BCRP-mediated drug efflux at the blood-brain barrier, ABCG2-mediated chemotherapy resistance, and ABCG2-related hyperuricemia/gout (the Q141K variant is one of the strongest genetic risk factors for gout).

Yes. ABCG2/BCRP rescue experiments are well-established for drug transporter research: • Construct design: use a codon-modified ABCG2 sequence with a small intracellular tag (FLAG, HA) — ABCG2 is an ABC half-transporter (single nucleotide-binding domain + transmembrane domain) functioning as a homodimer; tag placement should preserve dimerization and transport. • Surface localization validation: confirm plasma membrane localization by cell surface staining (5D3 antibody) before efflux assays. • Transport-deficient rescue: K86M Walker A mutation abolishes ATP-dependent transport. • Q141K polymorphism rescue: the common Q141K reduced-function variant enables gout and drug pharmacokinetics pharmacogenomic studies. • Functional readout: rescue should restore substrate efflux measured by mitoxantrone/Hoechst 33342 accumulation assays. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

ACVR2A and ACVR2B are the two type II activin receptors — serine/threonine kinase receptors that bind activins, myostatin (GDF8), GDF11, BMPs, and other TGF-β superfamily ligands; upon ligand binding, the type II receptor recruits and phosphorylates type I receptors (ALK4/ACVR1B, ALK5, ALK7), which then phosphorylate SMAD2/3 (activin/myostatin branch) to regulate gene expression. ACVR2A and ACVR2B share substantial ligand and functional overlap, with myostatin/GDF11-mediated muscle growth suppression being a major shared function. This ligand-trap axis is the basis of several clinically important therapeutics. The choice between knockout and overexpression depends on whether you are studying ACVR2A-specific activin/myostatin signaling. This ACVR2A Knockout in HEK293 is a workhorse mechanistic platform — HEK293 supports systematic structure-function studies of ACVR2A-mediated SMAD2/3 signaling. Overexpression is useful for studying ACVR2A gain-of-function effects. Important consideration: ACVR2A and ACVR2B share substantial ligand binding and functional overlap — single ACVR2A knockout may show modest phenotypes if ACVR2B compensates. This product complements the parallel ACVR2A Knockout in HAP1 and the ACVR2A & ACVR2B Double Knockout in HEK293 (both also available) for systematic paralog dissection. Rescue with wild-type or kinase-dead ACVR2A is the standard specificity control. The knockout is a critical specificity tool for ⭐⭐ sotatercept (Winrevair, FDA-approved 2024 ActRIIA-Fc ligand trap for pulmonary arterial hypertension), luspatercept (Reblozyl, ActRIIB-Fc trap for anemia in MDS/β-thalassemia), bimagrumab (anti-ActRII antibody for muscle/metabolic disease), and emerging activin/myostatin pathway-targeted therapeutics.

Yes. ACVR2A rescue experiments are well-established for activin receptor research: • Construct design: use a codon-modified ACVR2A sequence with a small intracellular C-terminal tag (FLAG, HA). ACVR2A has extracellular ligand-binding domain, single transmembrane span, and intracellular serine/threonine kinase domain — preserve all elements. • Surface localization validation: confirm plasma membrane localization before ligand binding studies. • Kinase-dead rescue: K219R mutation in the ATP-binding lysine abolishes catalytic activity. • Ligand-binding-deficient rescue: extracellular domain mutations disrupt activin/myostatin binding. • Functional readout: rescue should restore activin/myostatin-induced phospho-SMAD2/3 signaling. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying APP (amyloid precursor protein)'s role as the principal precursor of Aβ peptides or modeling Alzheimer's disease (AD). The Knockout line is the standard tool for asking whether APP is required for these processes — APP is a type I transmembrane glycoprotein processed by α-secretase (ADAM10, non-amyloidogenic) or sequentially by β-secretase (BACE1) and γ-secretase (presenilin complex) to generate amyloidogenic Aβ peptides (Aβ40, Aβ42); Aβ42 oligomerization and plaque deposition are central to Alzheimer's pathology. APP mutations (Swedish KM670/671NL, London V717I, Arctic E693G, others) cause familial early-onset AD. Overexpression is useful for studying APP gain-of-function effects. For Alzheimer's disease research, the EDITGENE APP Knockout in HEK293 is uniquely valuable — HEK293 supports systematic structure-function studies. Rescue with wild-type, Swedish mutation (increases Aβ production), or A673T protective mutation (Icelandic variant reducing Aβ) enables comprehensive AD modeling. The knockout is a critical specificity tool for ⭐⭐⭐ anti-Aβ antibodies: ⭐⭐⭐ lecanemab (Leqembi, FDA-approved 2023), donanemab (Kisunla, FDA-approved 2024), aducanumab (Aduhelm, withdrawn 2024); ⭐ BACE1 inhibitors (verubecestat, lanabecestat — abandoned in late-stage trials); γ-secretase modulators; emerging APP-targeted strategies.

Yes. APP rescue experiments are gold-standard for Alzheimer's disease research: • Construct design: use a codon-modified APP sequence with a small intracellular C-terminal tag (FLAG, HA, after AICD). APP is a type I transmembrane glycoprotein — preserve membrane topology and secretase cleavage sites. • Familial AD mutation rescue: Swedish KM670/671NL (increases all Aβ), London V717I (increases Aβ42/Aβ40 ratio), Arctic E693G (oligomerization-prone), Icelandic A673T (protective, reduces Aβ). • Surface localization validation: confirm plasma membrane APP and proper secretase processing. • Functional readout: rescue should restore Aβ40, Aβ42 production measured by conditioned media ELISA. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for Alzheimer's disease drug development.

The choice depends on whether you are studying ABCB1 (P-glycoprotein, P-gp, MDR1)'s role as the prototypical multidrug efflux transporter or modeling its central functions in drug resistance and pharmacokinetics. The Knockout line is the standard tool for asking whether ABCB1/P-gp is required for these processes — ABCB1/P-gp is the founding member of the ABC drug-efflux transporters, a full-transporter that effluxes an extraordinarily broad range of hydrophobic substrates including chemotherapeutics (doxorubicin, paclitaxel, vinblastine, imatinib), HIV protease inhibitors, immunosuppressants, and CNS drugs; P-gp is highly expressed at the blood-brain barrier, intestine, liver, and kidney, fundamentally shaping drug pharmacokinetics, and is the classical mediator of cancer multidrug resistance. Overexpression is useful for studying ABCB1 gain-of-function effects. For multidrug resistance and pharmacokinetics research, the EDITGENE ABCB1 Knockout in HEK293 is uniquely valuable — P-gp is the single most studied multidrug resistance transporter. Rescue with wild-type or transport-deficient ABCB1 enables structure-function studies. The knockout is a critical specificity tool for studying P-gp-mediated chemotherapy resistance, P-gp inhibitors (verapamil, tariquidar, elacridar, valspodar), blood-brain barrier drug penetration (P-gp is a major obstacle to CNS drug delivery), and drug-drug interaction pharmacokinetics — P-gp is a required transporter in FDA/EMA drug-drug interaction guidance.

Yes. ABCB1/P-gp rescue experiments are well-established for drug transporter research: • Construct design: use a codon-modified ABCB1 sequence with a small intracellular tag (FLAG, HA). P-gp is a full ABC transporter with two transmembrane domains and two nucleotide-binding domains — preserve membrane topology and the broad substrate-binding pocket. • Surface localization validation: confirm plasma membrane localization by cell surface staining (UIC2 antibody) before efflux assays. • Transport-deficient rescue: K433M/K1076M Walker A mutations abolish ATP-dependent transport. • Functional readout: rescue should restore substrate efflux measured by rhodamine 123/calcein-AM accumulation assays. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying ALOX5 (5-lipoxygenase, 5-LOX)'s role as the principal leukotriene-synthesizing enzyme or modeling asthma and emerging cancer applications. The Knockout line is the standard tool for asking whether 5-LOX is required for these processes — ALOX5 catalyzes the conversion of arachidonic acid to 5-HPETE and subsequently to LTA4 (in concert with FLAP/ALOX5AP), the precursor of all leukotrienes; 5-LOX is critical for neutrophil/eosinophil activation, bronchoconstriction in asthma, and atherosclerosis. Overexpression is useful for studying 5-LOX gain-of-function effects. For leukotriene biology research, the EDITGENE ALOX5 Knockout in HEK293 is uniquely valuable for studying the principal leukotriene-synthesizing enzyme. This product complements the parallel ALOX5AP/FLAP Knockout in HEK293 (also available) for systematic 5-LOX pathway dissection. Rescue with wild-type or catalytically-dead ALOX5 enables structure-function studies. The knockout is a critical specificity tool for ⭐ zileuton (Zyflo, FDA-approved 5-LOX inhibitor for asthma), MK-0633, and emerging 5-LOX-targeted approaches; CysLT1 receptor antagonists (montelukast/Singulair, zafirlukast) target the downstream cysteinyl leukotriene pathway.

Yes. ALOX5 rescue experiments are well-established for leukotriene biology: • Construct design: use a codon-modified ALOX5 sequence with a small C-terminal tag (FLAG, HA). ALOX5 has N-terminal C2-like (calcium/membrane binding) and C-terminal catalytic domain with active site iron — preserve all elements. • Catalytically-dead rescue: H367A/H372A/H550A iron-binding histidine mutations abolish lipoxygenase activity. • Zileuton-resistant rescue: gatekeeper or specific active site mutations can confer zileuton resistance for on-target validation. • Functional readout: rescue should restore 5-HPETE and leukotriene synthesis in arachidonic acid-stimulated cells. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying ABCD1 (adrenoleukodystrophy protein, ALDP)'s role as the peroxisomal VLCFA transporter or modeling X-linked adrenoleukodystrophy (X-ALD). The Knockout line is the standard tool for asking whether ABCD1 is required for these processes — ABCD1 is a peroxisomal ABC half-transporter that imports very-long-chain fatty acids (VLCFA, C24:0, C26:0) as CoA esters into peroxisomes for β-oxidation; ABCD1 dysfunction causes VLCFA accumulation. Overexpression is useful for studying ABCD1 gain-of-function effects. For peroxisomal disease research, the EDITGENE ABCD1 Knockout in HEK293 is uniquely valuable — ABCD1 loss-of-function mutations cause ⭐⭐ X-linked adrenoleukodystrophy (X-ALD), the most common peroxisomal disorder, with phenotypes ranging from childhood cerebral ALD (the basis of the 'Lorenzo's Oil' story) to adrenomyeloneuropathy (AMN); X-ALD is characterized by VLCFA accumulation, demyelination, and adrenal insufficiency. ABCD2 and ABCD3 paralog expression analysis aids interpretation. Rescue with wild-type or patient-derived ABCD1 mutations enables disease modeling. The knockout is valuable for studying peroxisomal VLCFA metabolism, X-ALD disease mechanisms, and emerging therapeutic approaches (Lorenzo's Oil, Lenmeldy/related gene therapy, Skysona/elivaldogene autotemcel — the FDA-approved 2022 gene therapy for cerebral ALD).

Yes. ABCD1 rescue experiments require attention to peroxisomal membrane targeting: • Construct design: use a codon-modified ABCD1 sequence with a small tag (FLAG, HA). ABCD1 is a peroxisomal ABC half-transporter (one transmembrane domain + one nucleotide-binding domain) functioning as a homodimer — preserve peroxisomal targeting. • Peroxisomal localization validation: confirm peroxisomal membrane localization before functional assays. • Transport-deficient rescue: Walker A/B motif mutations abolish ATP-dependent VLCFA transport. • X-ALD mutation rescue: patient-derived ABCD1 mutations enable disease modeling. • Functional readout: rescue should restore VLCFA peroxisomal import and β-oxidation, reducing C26:0 accumulation. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.